Prospects for better tuberculosis vaccines

Lancet Infectious Diseases

Volumn 1, Issue 1, 2001, Pages 21-28

  Collins, Helen L ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; LIVE VACCINE; SUBUNIT VACCINE;

ANIMAL; DISEASE MODEL; HUMAN; IMMUNOLOGY; REVIEW; STANDARD; TUBERCULOSIS;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; HUMANS; TUBERCULOSIS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 0035436970     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00018-4     Document Type: Review

References (38)

1. World Health Organisation. Global tuberculosis control, WHO report 2000. Geneva: WHO; 2001.
2. Kaufmann S.H.E. Is the development of a new tuberculosis vaccine possible? Nat Med. 6:2000;955-960.
3. Colditz G.A., Brewer T.F., Berkey C.S., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta analysis of the published literature. JAMA. 271:1994;698-702.
4. Fine P.E.M., Vynnycky E. The effect of heterologous immunity upon the apparent efficacy of (eg, BCG) vaccines. Vaccine. 16:1998;1923-1928.
5. Elias D., Wolday D., Akuffo H., Petros B., Bronner U., Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol. 123:2001;219-225.
6. Murray C.J.L., Salomon J.A. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci USA. 95:1998;13881-13886.
7. Medzhitov R., Janeway C. Jr. The Toll receptor family and microbial recognition. Trends Microbiol. 8:2000;452-456.
8. Hess J., Schaible U.E., Raupach B., Kaufmann S.H.E. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol. 75:2000;1-88.
9. Kaufmann S.H.E. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA. 93:1996;2272-2279.
10. Stenger S., Hanson D.A., Teitelbaum R., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 282:1998;121-125.
11. van Rie A., Warren R., Richardson M., et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 341:1999;1174-1179.
12. Orme I.M., McMurray D.N., Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9:2001;115-118.
13. Cole S.T., Brosch R., Parkhill J., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 93:1998;537-544.
14. Jungblut P.R., Schaible U.E., Mollenkopf H.J., et al. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol. 33:1999;1103-1117.
15. Vogel F.R. Improving vaccine performance with adjuvants. Clin Infect Dis. 30:2000;S266-S270.
16. Cox J.S., Chen B., McNeil M., Jacobs W.R.J.r. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. 402:2001;79-83.
17. McKinney J.D., Höner zu Bentrup K., Munoz-Elias E.J., et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 406:2000;735-738.
18. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., Kaufmann S.H.E. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA. 95:1998;5299-5304.
19. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA. 97:2000;13853-13858.
20. Hess J., Grode L., Hellwig J., et al. Protection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa antigen of Mycobacterium bovis BCG. FEMS Immunol Microbiol. 27:2000;283-289.
21. Smith D.A., Parrish T., Stoker N.G., Bancroft G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun. 69:2001;1142-1150.
22. Brandt L., Elhay M., Rosenkrands I., Lindblad E., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun. 68:2000;791-795.
23. Pehler K., Brasky K.M., Butler T.M., Attanasio R. Mycobacterium tuberculosis secreted protein antigens: immunogenicity in baboons. J Clin Immunol. 20:2000;306-316.
24. Olsen A.W., van Pinxteren L.A.H., Okkels L.M., Rasmussen P.B., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun. 69:2001;2773-2778.
25. Brooks J.V., Frank A.A., Keen M.A., Belisle J.T., Orme I.M. Boosting vaccine for tuberculosis. Infect Immun. 69:2001;2714-2717.
26. Jones T.R., Narum D.L., Gozalo A.S., et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regime. J Infect Dis. 183:2001;303-312.
27. Tanghe A., D'Souza S., Rosseels V. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag 85 by protein boosting. Infect Immun. 69:2001;3041-3047.
28. Tascon R.E., Soares C.S., Ragno S., Stavropoulos E., Hirst E.M.A., Colston M.J. Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. Immunology. 99:2000;473-480.
29. Baldwin S.L., D'Souza C., Roberts A.D. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun. 66:1998;2951-2959.
30. Lowrie D.B., Tascon R.E., Bonato V.L.D. Therapy of tuberculosis in mice by DNA vaccination. Nature. 400:1999;269-271.
31. Turner O.C., Roberts A.D., Frank A.A. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunised with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect Immun. 68:2000;3674-3679.
32. Melby P.C., Ogden G.B., Flores H.A. Identification of vaccine candidates for experimental visceral leishmaniasis by immunisation with sequential fractions of a cDNA expression library. Infect Immun. 68:2000;5595-5602.
33. Comstock G.W. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine. Clin Infect Dis. 30:2000;S250-S253.
34. McMurray D.N. A nonhuman primate model for preclinicaltesting of new tuberculosis vaccines. Clin Infect Dis. 30:2000;S210-S212.
35. Ellner J.J., Hirsch C.S., Whalen C.C. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis. 30:2000;S279-S282.
36. Elliott A.M., Hurst T.J., Baleyeku M.N. The immune responseto Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assayin an epidemiological study. Int J Tuberc Lung Dis. 3:1999;239-247.
37. Munk M.E., Arend S.M., Brock I., Ottenhoff T.M., Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J Infect Dis. 183:2001;175-176.
38. Kampmann B., Gaora P.O., Snewin V.A., Gares M.P., Young D.B., Levin M. Evaluation of human antimycobacterial immunityusing recombinant reporter mycobacteria. J Infect Dis. 182:2000;895-901.